Tags

Type your tag names separated by a space and hit enter

Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
Circulation. 2005 Apr 19; 111(15):1924-31.Circ

Abstract

BACKGROUND

Obesity may independently increase the risk of adverse events in hypertension with target-organ damage. We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan relative to atenolol influenced the impact of body build on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and on cardiovascular death in patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.

METHODS AND RESULTS

The population of 9079 patients was divided as follows: thin (body mass index [BMI] <20 kg/m2, 2%), normal weight (BMI 20 to 24.9, 24%), overweight (BMI 25 to 29.9, 45%), and obese (class I: BMI 30 to 34.9, 21%; class II: BMI 35 to 39.9, 6%; class III: BMI > or =40, 2%). Incident diabetes increased progressively with BMI and was somewhat higher in the atenolol arm. Differences in gender and race were detected among the body build groups. Rates (Cox proportional hazard analysis) of the primary composite end point did not differ among body build groups after adjustment for age, gender, race, smoking habit, prevalent cardiovascular disease, and left ventricular hypertrophy. Cardiovascular death was more frequent among thin (P<0.05) and pooled class II-III obesity (both P<0.04) than normal-weight groups. Risk was not attenuated significantly by losartan treatment, nor did it interfere with the greater benefit of losartan- as opposed to atenolol-based treatment.

CONCLUSIONS

In the LIFE study, stratification for classes of body build identified increased risk of cardiovascular mortality in both thin and moderately-to-severely obese individuals. This risk was not attenuated significantly by losartan treatment, nor did it interfere with the greater benefit of losartan-based treatment as opposed to atenolol-based treatment.

Authors+Show Affiliations

Department of Clinical and Experimental Medicine, Federico II University Hospital, via S. Pansini, No. 5, 80131 Naples, Italy. simogi@unina.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15837945

Citation

de Simone, Giovanni, et al. "Body Build and Risk of Cardiovascular Events in Hypertension and Left Ventricular Hypertrophy: the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) Study." Circulation, vol. 111, no. 15, 2005, pp. 1924-31.
de Simone G, Wachtell K, Palmieri V, et al. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. Circulation. 2005;111(15):1924-31.
de Simone, G., Wachtell, K., Palmieri, V., Hille, D. A., Beevers, G., Dahlöf, B., de Faire, U., Fyhrquist, F., Ibsen, H., Julius, S., Kjeldsen, S. E., Lederballe-Pedersen, O., Lindholm, L. H., Nieminen, M. S., Omvik, P., Oparil, S., & Devereux, R. B. (2005). Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. Circulation, 111(15), 1924-31.
de Simone G, et al. Body Build and Risk of Cardiovascular Events in Hypertension and Left Ventricular Hypertrophy: the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) Study. Circulation. 2005 Apr 19;111(15):1924-31. PubMed PMID: 15837945.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. AU - de Simone,Giovanni, AU - Wachtell,Kristian, AU - Palmieri,Vittorio, AU - Hille,Darcy A, AU - Beevers,Gareth, AU - Dahlöf,Björn, AU - de Faire,Ulf, AU - Fyhrquist,Frej, AU - Ibsen,Hans, AU - Julius,Stevo, AU - Kjeldsen,Sverre E, AU - Lederballe-Pedersen,Ole, AU - Lindholm,Lars H, AU - Nieminen,Markku S, AU - Omvik,Per, AU - Oparil,Suzanne, AU - Devereux,Richard B, PY - 2005/4/20/pubmed PY - 2005/11/16/medline PY - 2005/4/20/entrez SP - 1924 EP - 31 JF - Circulation JO - Circulation VL - 111 IS - 15 N2 - BACKGROUND: Obesity may independently increase the risk of adverse events in hypertension with target-organ damage. We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan relative to atenolol influenced the impact of body build on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and on cardiovascular death in patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. METHODS AND RESULTS: The population of 9079 patients was divided as follows: thin (body mass index [BMI] <20 kg/m2, 2%), normal weight (BMI 20 to 24.9, 24%), overweight (BMI 25 to 29.9, 45%), and obese (class I: BMI 30 to 34.9, 21%; class II: BMI 35 to 39.9, 6%; class III: BMI > or =40, 2%). Incident diabetes increased progressively with BMI and was somewhat higher in the atenolol arm. Differences in gender and race were detected among the body build groups. Rates (Cox proportional hazard analysis) of the primary composite end point did not differ among body build groups after adjustment for age, gender, race, smoking habit, prevalent cardiovascular disease, and left ventricular hypertrophy. Cardiovascular death was more frequent among thin (P<0.05) and pooled class II-III obesity (both P<0.04) than normal-weight groups. Risk was not attenuated significantly by losartan treatment, nor did it interfere with the greater benefit of losartan- as opposed to atenolol-based treatment. CONCLUSIONS: In the LIFE study, stratification for classes of body build identified increased risk of cardiovascular mortality in both thin and moderately-to-severely obese individuals. This risk was not attenuated significantly by losartan treatment, nor did it interfere with the greater benefit of losartan-based treatment as opposed to atenolol-based treatment. SN - 1524-4539 UR - https://www.unboundmedicine.com/medline/citation/15837945/Body_build_and_risk_of_cardiovascular_events_in_hypertension_and_left_ventricular_hypertrophy:_the_LIFE__Losartan_Intervention_For_Endpoint_reduction_in_hypertension__study_ L2 - https://www.ahajournals.org/doi/10.1161/01.CIR.0000161799.91577.0A?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -